GENMAB A/S (GNMSF:OTCMKTS)
$281.75 0.9 (0.3205%)
Analysed GENMAB A/S (GNMSF:OTCMKTS) News Sources
Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence
22-04-2026
yahoo.com
Genmab (CPSE:GMAB) Valuation Check After Mixed Recent Share Performance
20-04-2026
yahoo.com
Genmab A/S Share Capital Reduction
17-04-2026
yahoo.com
Major Shareholder Announcement
14-04-2026
yahoo.com
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14-04-2026
yahoo.com
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
13-04-2026
yahoo.com
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
01-04-2026
yahoo.com
A Look At Genmab’s (CPSE:GMAB) Valuation After Recent Share Price Volatility
01-04-2026
yahoo.com
Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls
27-03-2026
yahoo.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
27-03-2026
247wallst.com
What is the current price of GENMAB A/S (GNMSF:OTCMKTS)?
The current price of GENMAB A/S (GNMSF:OTCMKTS) is $281.75.
GENMAB A/S (GNMSF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of GENMAB A/S (GNMSF:OTCMKTS) since the previous trading day is $0.9.
GENMAB A/S (GNMSF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of GENMAB A/S (GNMSF:OTCMKTS) since the previous trading day is 0.3205%.
What is the most recent average sentiment score for GENMAB A/S (GNMSF:OTCMKTS)?
The most recent average sentiment score for GENMAB A/S (GNMSF:OTCMKTS) is 71 out of 100.
What is the most recent average sentiment for GENMAB A/S (GNMSF:OTCMKTS)?
The most recent sentiment for GENMAB A/S (GNMSF:OTCMKTS) is .
SEC-8K** Filing Available For GENMAB A/S (GNMSF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.